[Immunological studies on insulin-dependent diabetes mellitus (IDDM). I. Natural killer (NK) cell activity].

T. Tomoda,F. Hamada,N. Zushi,T. Kurashige,I. Kitamura,T. Kunitomi

1987-03-01

Abstract:

What problem does this paper attempt to address?

Early human B cell signatures of the primary antibody response to mRNA vaccination

Lela Kardava,Nicholas Rachmaninoff,William W. Lau,Clarisa M. Buckner,Krittin Trihemasava,Jana Blazkova,Felipe Lopes de Assis,Wei Wang,Xiaozhen Zhang,Yimeng Wang,Chi-I Chiang,Sandeep Narpala,Genevieve E. McCormack,Can Liu,Catherine A. Seamon,Michael C. Sneller,Sarah O’Connell,Yuxing Li,Adrian B. McDermott,Tae-Wook Chun,Anthony S. Fauci,John S. Tsang,Susan Moir

DOI: https://doi.org/10.1073/pnas.2204607119

IF: 11.1

2022-06-27

Proceedings of the National Academy of Sciences

Abstract:Messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective at inducing protective immunity. However, weak antibody responses are seen in some individuals, and cellular correlates of immunity remain poorly defined, especially for B cells. Here we used unbiased approaches to longitudinally dissect primary antibody, plasmablast, and memory B cell (MBC) responses to the two-dose mRNA-1273 vaccine in SARS-CoV-2–naive adults. Coordinated immunoglobulin A (IgA) and IgG antibody responses were preceded by bursts of spike-specific plasmablasts after both doses but earlier and more intensely after dose 2. While antibody and B cell cellular responses were generally robust, they also varied within the cohort and decreased over time after a dose-2 peak. Both antigen-nonspecific postvaccination plasmablast frequency after dose 1 and their spike-specific counterparts early after dose 2 correlated with subsequent antibody levels. This correlation between early plasmablasts and antibodies remained for titers measured at 6 months after vaccination. Several distinct antigen-specific MBC populations emerged postvaccination with varying kinetics, including two MBC populations that correlated with 2- and 6-month antibody titers. Both were IgG-expressing MBCs: one less mature, appearing as a correlate after the first dose, while the other MBC correlate showed a more mature and resting phenotype, emerging as a correlate later after dose 2. This latter MBC was also a major contributor to the sustained spike-specific MBC response observed at month 6. Thus, these plasmablasts and MBCs that emerged after both the first and second doses with distinct kinetics are potential determinants of the magnitude and durability of antibodies in response to mRNA-based vaccination.

multidisciplinary sciences
Dyscrasias with "undetermined significance".

G. Burg,R. Dummer,W. Kempf

DOI: https://doi.org/10.1001/ARCHDERM.141.3.382

2005-03-01

Archives of Dermatology

Abstract:
Affinity-independent memory B cell origin of the early antibody-secreting cell response in naive individuals upon SARS-CoV-2 vaccination

Zhe Li,Anna Obraztsova,Fuwei Shang,Opeyemi Ernest Oludada,Joshua Malapit,Katrin Busch,Monique van Straaten,Erec Stebbins,Rajagopal Murugan,Hedda Wardemann

DOI: https://doi.org/10.1016/j.immuni.2024.07.023

IF: 32.4

2024-08-13

Immunity

Abstract:Memory B cells (MBCs) formed over the individual's lifetime constitute nearly half of the circulating B cell repertoire in humans. These pre-existing MBCs dominate recall responses to their cognate antigens, but how they respond to recognition of novel antigens is not well understood. Here, we tracked the origin and followed the differentiation paths of MBCs in the early anti-spike (S) response to mRNA vaccination in SARS-CoV-2-naive individuals on single-cell and monoclonal antibody levels. Pre-existing, highly mutated MBCs showed no signs of germinal center re-entry and rapidly developed into mature antibody-secreting cells (ASCs). By contrast, and despite similar levels of S reactivity, naive B cells showed strong signs of antibody affinity maturation before differentiating into MBCs and ASCs. Thus, pre-existing human MBCs differentiate into ASCs in response to novel antigens, but the quality of the humoral and cellular anti-S response improved through the clonal selection and affinity maturation of naive precursors.
Long-Lasting Enhanced Cytokine Responses Following SARS-CoV-2 BNT162b2 mRNA Vaccination

Georgiana Cabău,Medeea Badii,Andreea M Mirea,Orsolya I Gaal,Liesbeth van Emst,Radu A Popp,Tania O Crișan,Leo A B Joosten

DOI: https://doi.org/10.3390/vaccines12070736

2024-07-03

Abstract:The mRNA vaccine against COVID-19 protects against severe disease by the induction of robust humoral and cellular responses. Recent studies have shown the capacity of some vaccines to induce enduring non-specific innate immune responses by the induction of trained immunity, augmenting protection against unrelated pathogens. This study aimed to assess whether the mRNA vaccine BNT162b2 can induce lasting non-specific immune responses in myeloid cells following a three-dose vaccination scheme. In a sample size consisting of 20 healthy individuals from Romania, we assessed inflammatory proteins using the Olink® Target 96 Inflammation panel, as well as ex vivo cytokine responses following stimulations with unrelated PRR ligands. We assessed the vaccine-induced non-specific systemic inflammation and functional adaptations of myeloid cells. Our results revealed the induction of a stimulus- and cytokine-dependent innate immune memory phenotype that became apparent after the booster dose and was maintained eight months later in the absence of systemic inflammation.
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang,Fabian Schmidt,Yiska Weisblum,Frauke Muecksch,Christopher O. Barnes,Shlomo Finkin,Dennis Schaefer-Babajew,Melissa Cipolla,Christian Gaebler,Jenna A. Lieberman,Thiago Y. Oliveira,Zhi Yang,Morgan E. Abernathy,Kathryn E. Huey-Tubman,Arlene Hurley,Martina Turroja,Kamille A. West,Kristie Gordon,Katrina G. Millard,Victor Ramos,Justin Da Silva,Jianliang Xu,Robert A. Colbert,Roshni Patel,Juan Dizon,Cecille Unson-O’Brien,Irina Shimeliovich,Anna Gazumyan,Marina Caskey,Pamela J. Bjorkman,Rafael Casellas,Theodora Hatziioannou,Paul D. Bieniasz,Michel C. Nussenzweig

DOI: https://doi.org/10.1038/s41586-021-03324-6

IF: 64.8

2021-02-10

Nature

Abstract:Here we report on the antibody and memory B cell responses in a cohort of 20 volunteers who received either the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines1–4. Eight weeks after the second vaccine injection volunteers showed high levels of IgM, and IgG anti-SARS-CoV-2 spike protein (S) and receptor binding domain (RBD) binding titers. Moreover, the plasma neutralizing activity, and the relative numbers of RBD-specific memory B cells were equivalent to individuals who recovered from natural infection5,6. However, activity against SARS-CoV-2 variants encoding E484K or N501Y or the K417N:E484K:N501Y combination was reduced by a small but significant margin. Vaccine-elicited monoclonal antibodies (mAbs) potently neutralize SARS-CoV-2, targeting a number of different RBD epitopes in common with mAbs isolated from infected donors5–8. However, neutralization by 14 of the 17 most potent mAbs tested was reduced or abolished by either K417N, or E484K, or N501Y mutations. Notably, the same mutations were selected when recombinant vesicular stomatitis virus (rVSV)/SARS-CoV-2 S was cultured in the presence of the vaccine elicited mAbs. Taken together the results suggest that the monoclonal antibodies in clinical use should be tested against newly arising variants, and that mRNA vaccines may need to be updated periodically to avoid potential loss of clinical efficacy.

multidisciplinary sciences
Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination – kinetics of plasma antibodies, plasmablasts and memory B cells

Kilian A. Wietschel,Kevin Fechtner,Elmer Antileo,Goran Abdurrahman,Chiara A. Drechsler,Michelle Kudzayi Makuvise,Ruben Rose,Mathias Voß,Andi Krumbholz,Stephan Michalik,Stefan Weiss,Lena Ulm,Philipp Franikowski,Helmut Fickenscher,Barbara M. Bröker,Dina Raafat,Silva Holtfreter

DOI: https://doi.org/10.3389/fimmu.2024.1382911

IF: 7.3

2024-05-15

Frontiers in Immunology

Abstract:Introduction: COVID-19 vaccines are highly effective in inducing protective immunity. While the serum antibody response to COVID-19 vaccination has been studied in depth, our knowledge of the underlying plasmablast and memory B cell (Bmem) responses is still incomplete. Here, we determined the antibody and B cell response to COVID-19 vaccination in a naïve population and contrasted it with the response to a single influenza vaccination in a primed cohort. In addition, we analyzed the antibody and B cell responses against the four endemic human coronaviruses (HCoVs). Methods: Measurement of specific plasma IgG antibodies was combined with functional analyses of antibody-secreting plasmablasts and Bmems. SARS-CoV-2- and HCoV-specific IgG antibodies were quantified with an in-house bead-based multiplexed immunoassay. Results: The antibody and B cell responses to COVID-19 vaccination reflected the kinetics of a prime-boost immunization, characterized by a slow and moderate primary response and a faster and stronger secondary response. In contrast, the influenza vaccinees possessed robust immune memory for the vaccine antigens prior to vaccination, and the recall vaccination moderately boosted antibody production and Bmem responses. Antibody levels and Bmem responses waned several months after the 2 nd COVID-19 vaccination, but were restored upon the 3 rd vaccination. The COVID-19 vaccine-induced antibodies mainly targeted novel, non-cross-reactive S1 epitopes of the viral spike protein, while cross-reactive S2 epitopes were less immunogenic. Booster vaccination not only strongly enhanced neutralizing antibodies against an original SARS-CoV-2 strain, but also induced neutralizing antibodies against the Omicron BA.2 variant. We observed a 100% plasma antibody prevalence against the S1 subunits of HCoVs, which was not affected by vaccination. Discussion: Overall, by complementing classical serology with a functional evaluation of plasmablasts and memory B cells we provide new insights into the specificity of COVID-19 vaccine-induced antibody and B cell responses.

immunology
Speak up ... if you dare: raising concerns about colleagues you suspect of bad practice is not easy in a working culture that views whistle-blowing as 'telling tales'.

S. Harrison

2003-01-15

Nursing Standard

Abstract:
SARS-CoV-2 Omicron BA.1 breakthrough infection drives late remodeling of the memory B cell repertoire in vaccinated individuals

Aurélien Sokal,Giovanna Barba-Spaeth,Lise Hunault,Ignacio Fernández,Matteo Broketa,Annalisa Meola,Slim Fourati,Imane Azzaoui,Alexis Vandenberghe,Pauline Lagouge-Roussey,Manon Broutin,Anais Roeser,Magali Bouvier-Alias,Etienne Crickx,Laetitia Languille,Morgane Fournier,Marc Michel,Bertrand Godeau,Sébastien Gallien,Giovanna Melica,Yann Nguyen,Florence Canoui-Poitrine,France Pirenne,Jérôme Megret,Jean-Michel Pawlotsky,Simon Fillatreau,Claude-Agnès Reynaud,Jean-Claude Weill,Félix A Rey,Pierre Bruhns,Matthieu Mahévas,Pascal Chappert

DOI: https://doi.org/10.1016/j.immuni.2023.07.007

IF: 32.4

2023-09-12

Immunity

Abstract:How infection by a viral variant showing antigenic drift impacts a preformed mature human memory B cell (MBC) repertoire remains an open question. Here, we studied the MBC response up to 6 months after SARS-CoV-2 Omicron BA.1 breakthrough infection in individuals previously vaccinated with three doses of the COVID-19 mRNA vaccine. Longitudinal analysis, using single-cell multi-omics and functional analysis of monoclonal antibodies from RBD-specific MBCs, revealed that a BA.1 breakthrough infection mostly recruited pre-existing cross-reactive MBCs with limited de novo response against BA.1-restricted epitopes. Reorganization of clonal hierarchy and new rounds of germinal center reactions, however, combined to maintain diversity and induce progressive maturation of the MBC repertoire against common Hu-1 and BA.1, but not BA.5-restricted, SARS-CoV-2 Spike RBD epitopes. Such remodeling was further associated with a marked improvement in overall neutralizing breadth and potency. These findings have fundamental implications for the design of future vaccination booster strategies.
Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections

Salomé Desmecht,Aleksandr Tashkeev,Majdouline El Moussaoui,Nicole Marechal,Hélène Perée,Yumie Tokunaga,Celine Fombellida-Lopez,Barbara Polese,Céline Legrand,Marie Wéry,Myriam Mni,Nicolas Fouillien,Françoise Toussaint,Laurent Gillet,Fabrice Bureau,Laurence Lutteri,Marie-Pierre Hayette,Michel Moutschen,Christelle Meuris,Pieter Vermeersch,Daniel Desmecht,Souad Rahmouni,Gilles Darcis

DOI: https://doi.org/10.3389/fimmu.2022.863554

IF: 7.3

2022-06-01

Frontiers in Immunology

Abstract:Background: Understanding and measuring the individual level of immune protection and its persistence at both humoral and cellular levels after SARS-CoV-2 vaccination is mandatory for the management of the vaccination booster campaign. Our prospective study was designed to assess the immunogenicity of the BNT162b2 mRNA vaccine in triggering the cellular and humoral immune response in healthcare workers up to 12 months after the initial vaccination, with one additional boosting dose between 6 and 12 months. Methods: This prospective study enrolled 208 healthcare workers (HCWs) from the Liège University Hospital (CHU) of Liège in Belgium. Participants received two doses of BioNTech/Pfizer COVID-19 vaccine (BNT162b2) and a booster dose 6-12 months later. Fifty participants were SARS-CoV-2 experienced and 158 were naïve before the vaccination. Blood sampling was performed at the day of the first (T0) and second (T1) vaccine doses administration, then at 2 weeks (T2), 4 weeks (T3), 6 months (T4) and 12 months (T5) after the second dose. Between T4 and T5, participants also got the third boosting vaccine dose. A total of 1145 blood samples were collected. All samples were tested for the presence of anti-Spike antibodies, using the DiaSorin LIAISON SARS-CoV-2 Trimeric S IgG assay, and for anti-Nucleocapsid antibodies, using Elecsys anti-SARS-CoV-2 assay. Neutralizing antibodies against the SARS-CoV-2 Wuhan-like variant strain were quantified in all samples using a Vero E6 cell-based neutralization assay. Cell-mediated immune response was evaluated at T4 and T5 on 80 and 55 participants, respectively, by measuring the secretion of IFN-γ on peripheral blood lymphocytes using the QuantiFERON Human IFN-γ SARS-CoV-2, from Qiagen. We analyzed separately the naïve and experienced participants. Findings: We found that anti-spike antibodies and neutralization capacity levels were significantly higher in SARS-CoV-2 experienced HCWs compared to naïve HCWs at all time points analyzed except the one after boosting dose. Cellular immune response was also higher in experienced HCWs six months following vaccination. Besides the impact of SARS-CoV-2 infection history on immune response to BNT162b2 mRNA vaccine, we observed a significant negative association between age and persistence of humoral response. The booster dose induced an increase in humoral and cellular immune responses, particularly in naive individuals. Breakthrough infections resulted in higher cellular and humoral responses after the booster dose. Conclusions: Our data strengthen previous findings demonstrating that immunization through vaccination combined with natural infection is better than 2 vaccine doses immunization or natural infection alone. The benefit of the booster dose was greater in naive individuals. It may have implications for personalizing mRNA vaccination regimens used to prevent severe COVID-19 and reduce the impact of the pandemic on the healthcare system. More specifically, it may help prioritizing vaccination, including for the deployment of booster doses.

immunology
Cellular basis of enhanced humoral immunity to SARS-CoV-2 upon homologous or heterologous booster vaccination analyzed by single-cell immune profiling

Jingwen Ai,Jingxin Guo,Haocheng Zhang,Yi Zhang,Haochen Yang,Ke Lin,Jieyu Song,Zhangfan Fu,Mingxiang Fan,Qiran Zhang,Hongyu Wang,Yuanhan Zhao,Zhangyufan He,An Cui,Yang Zhou,Jing Wu,Mingzhe Zhou,Guanmin Yuan,Boxi Kang,Ning Zhao,Yuanyuan Xu,Mengqi Zhu,Youhong Wang,Zemin Zhang,Ning Jiang,Chao Qiu,Chenqi Xu,Wenhong Zhang

DOI: https://doi.org/10.1038/s41421-022-00480-5

IF: 38.079

2022-10-22

Cell Discovery

Abstract:SARS-CoV-2 vaccine booster dose can induce a robust humoral immune response, however, its cellular mechanisms remain elusive. Here, we investigated the durability of antibody responses and single-cell immune profiles following booster dose immunization, longitudinally over 6 months, in recipients of a homologous BBIBP-CorV/BBIBP-CorV or a heterologous BBIBP-CorV/ZF2001 regimen. The production of neutralizing antibodies was dramatically enhanced by both booster regimens, and the antibodies could last at least six months. The heterologous booster induced a faster and more robust plasmablast response, characterized by activation of plasma cells than the homologous booster. The response was attributed to recall of memory B cells and the de novo activation of B cells. Expanded B cell clones upon booster dose vaccination could persist for months, and their B cell receptors displayed accumulated mutations. The production of antibody was positively correlated with antigen presentation by conventional dendritic cells (cDCs), which provides support for B cell maturation through activation and development of follicular helper T (Tfh) cells. The proper activation of cDC/Tfh/B cells was likely fueled by active energy metabolism, and glutaminolysis might also play a general role in promoting humoral immunity. Our study unveils the cellular mechanisms of booster-induced memory/adaptive humoral immunity and suggests potential strategies to optimize vaccine efficacy and durability in future iterations.

cell biology
Antibody feedback regulation of memory B cell development in SARS-CoV-2 mRNA vaccination

Dennis Schaefer-Babajew,Zijun Wang,Frauke Muecksch,Alice Cho,Raphael Raspe,Brianna Johnson,Marie Canis,Justin DaSilva,Victor Ramos,Martina Turroja,Katrina Millard,Fabian Schmidt,Juan Dizon,Irina Shimeliovich,Kai-Hui Yao,Thiago Oliveira,Anna Gazumyan,Christian Gaebler,Paul D. Bieniasz,Theodora Hatziioannou,Marina Caskey,Michel C. Nussenzweig

DOI: https://doi.org/10.1101/2022.08.05.22278483

2022-08-11

MedRxiv

Abstract:Feedback inhibition of humoral immunity by antibodies was initially documented in guinea pigs by Theobald Smith in 1909, who showed that passive administration of excess anti-Diphtheria toxin inhibited immune responses. Subsequent work documented that antibodies can enhance or inhibit immune responses depending on antibody isotype, affinity, the physical nature of the antigen, and engagement of immunoglobulin (Fc) and complement receptors. However, little is known about how pre-existing antibodies might influence the subsequent development of memory B cells. Here we examined the memory B cell response in individuals who received two high-affinity IgG1 anti-SARS-CoV-2 receptor binding domain (RBD)-specific monoclonal antibodies, C144-LS and C135-LS, and subsequently two doses of a SARS-CoV-2 mRNA vaccine. The two antibodies target Class 2 and 3 epitopes that dominate the initial immune response to SARS-CoV-2 infection and mRNA vaccination. Antibody responses to the vaccine in C144-LS and C135-LS recipients produced plasma antigen binding and neutralizing titers that were fractionally lower but not statistically different to controls. In contrast, memory B cells enumerated by flow cytometry after the second vaccine dose were present in higher numbers than in controls. However, the memory B cells that developed in antibody recipients differed from controls in that they were not enriched in VH3-53, VH1-46 and VH3-66 genes and predominantly expressed low-affinity IgM antibodies that carried small numbers of somatic mutations. These antibodies showed altered RBD target specificity consistent with epitope masking, and only 1 out of 77 anti-RBD memory antibodies tested neutralized the virus. The results indicate that pre-existing high-affinity antibodies bias memory B cell selection and have a profound effect on the development of immunological memory in humans that may in part explain the shifting target profile of memory antibodies elicited by the 3rd mRNA vaccine dose.
mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern

Rishi R. Goel,Mark M. Painter,Sokratis A. Apostolidis,Divij Mathew,Wenzhao Meng,Aaron M. Rosenfeld,Kendall A. Lundgreen,Arnold Reynaldi,David S. Khoury,Ajinkya Pattekar,Sigrid Gouma,Leticia Kuri-Cervantes,Philip Hicks,Sarah Dysinger,Amanda Hicks,Harsh Sharma,Sarah Herring,Scott Korte,Amy E. Baxter,Derek A. Oldridge,Josephine R. Giles,Madison E. Weirick,Christopher M. McAllister,Moses Awofolaju,Nicole Tanenbaum,Elizabeth M. Drapeau,Jeanette Dougherty,Sherea Long,Kurt D’Andrea,Jacob T. Hamilton,Maura McLaughlin,Justine C. Williams,Sharon Adamski,Oliva Kuthuru,Ian Frank,Michael R. Betts,Laura A. Vella,Alba Grifoni,Daniela Weiskopf,Alessandro Sette,Scott E. Hensley,Miles P. Davenport,Paul Bates,Eline T. Luning Prak,Allison R. Greenplate,E. John Wherry,

DOI: https://doi.org/10.1101/2021.08.23.457229

2021-08-23

Abstract:ABSTRACT SARS-CoV-2 mRNA vaccines have shown remarkable efficacy, especially in preventing severe illness and hospitalization. However, the emergence of several variants of concern and reports of declining antibody levels have raised uncertainty about the durability of immune memory following vaccination. In this study, we longitudinally profiled both antibody and cellular immune responses in SARS-CoV-2 naïve and recovered individuals from pre-vaccine baseline to 6 months post-mRNA vaccination. Antibody and neutralizing titers decayed from peak levels but remained detectable in all subjects at 6 months post-vaccination. Functional memory B cell responses, including those specific for the receptor binding domain (RBD) of the Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants, were also efficiently generated by mRNA vaccination and continued to increase in frequency between 3 and 6 months post-vaccination. Notably, most memory B cells induced by mRNA vaccines were capable of cross-binding variants of concern, and B cell receptor sequencing revealed significantly more hypermutation in these RBD variant-binding clones compared to clones that exclusively bound wild-type RBD. Moreover, the percent of variant cross-binding memory B cells was higher in vaccinees than individuals who recovered from mild COVID-19. mRNA vaccination also generated antigen-specific CD8+ T cells and durable memory CD4+ T cells in most individuals, with early CD4+ T cell responses correlating with humoral immunity at later timepoints. These findings demonstrate robust, multi-component humoral and cellular immune memory to SARS-CoV-2 and current variants of concern for at least 6 months after mRNA vaccination. Finally, we observed that boosting of pre-existing immunity with mRNA vaccination in SARS-CoV-2 recovered individuals primarily increased antibody responses in the short-term without significantly altering antibody decay rates or long-term B and T cell memory. Together, this study provides insights into the generation and evolution of vaccine-induced immunity to SARS-CoV-2, including variants of concern, and has implications for future booster strategies. GRAPHICAL ABSTRACT
Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing

Renyang Tong,Lingjie Luo,Yichao Zhao,Mingze Sun,Ronghong Li,Jianmei Zhong,Yifan Chen,Liuhua Hu,Zheng Li,Jianfeng Shi,Yuyan Lyu,Li Hu,Xiao Guo,Qi Liu,Tian Shuang,Chenjie Zhang,Ancai Yuan,Lingyue Sun,Zheng Zhang,Kun Qian,Lei Chen,Wei Lin,Alex F Chen,Feng Wang,Jun Pu

DOI: https://doi.org/10.1080/22221751.2023.2187245

Abstract:Over 3 billion doses of inactivated vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been administered globally. However, our understanding of the immune cell functional transcription and T cell receptor (TCR)/B cell receptor (BCR) repertoire dynamics following inactivated SARS-CoV-2 vaccination remains poorly understood. Here, we performed single-cell RNA and TCR/BCR sequencing on peripheral blood mononuclear cells at four time points after immunization with the inactivated SARS-CoV-2 vaccine BBIBP-CorV. Our analysis revealed an enrichment of monocytes, central memory CD4+ T cells, type 2 helper T cells and memory B cells following vaccination. Single-cell TCR-seq and RNA-seq comminating analysis identified a clonal expansion of CD4+ T cells (but not CD8+ T cells) following a booster vaccination that corresponded to a decrease in the TCR diversity of central memory CD4+ T cells and type 2 helper T cells. Importantly, these TCR repertoire changes and CD4+ T cell differentiation were correlated with the biased VJ gene usage of BCR and the antibody-producing function of B cells post-vaccination. Finally, we compared the functional transcription and repertoire dynamics in immune cells elicited by vaccination and SARS-CoV-2 infection to explore the immune responses under different stimuli. Our data provide novel molecular and cellular evidence for the CD4+ T cell-dependent antibody response induced by inactivated vaccine BBIBP-CorV. This information is urgently needed to develop new prevention and control strategies for SARS-CoV-2 infection. (ClinicalTrials.gov Identifier: NCT04871932).
Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination

Dennis Schaefer-Babajew,Zijun Wang,Frauke Muecksch,Alice Cho,Maximilian Loewe,Melissa Cipolla,Raphael Raspe,Brianna Johnson,Marie Canis,Justin DaSilva,Victor Ramos,Martina Turroja,Katrina G. Millard,Fabian Schmidt,Leander Witte,Juan Dizon,Kai-Hui Yao,Thiago Y. Oliveira,Anna Gazumyan,Christian Gaebler,Paul D. Bieniasz,Theodora Hatziioannou,Marina Caskey,Michel C. Nussenzweig,Irina Shimelovich

DOI: https://doi.org/10.1038/s41586-022-05609-w

IF: 64.8

2022-12-07

Nature

Abstract:Feedback inhibition of humoral immunity by antibodies was first documented in 1909 1 . Subsequent work showed that, depending on the context, antibodies can enhance or inhibit immune responses 2,3 . However, little is known about how pre-existing antibodies influence the development of memory B cells. Here we examined the memory B cell response in individuals who received two high-affinity anti-SARS-CoV-2 monoclonal antibodies, and subsequently two doses of an mRNA vaccine 4-8 . We found that monoclonal antibody recipients produced antigen binding and neutralizing titers that were only fractionally lower than controls. In contrast, their memory B cells differed from controls in that they predominantly expressed low-affinity IgM antibodies that carried small numbers of somatic mutations and showed altered RBD target specificity consistent with epitope masking. Moreover, only 1 out of 77 anti-RBD memory antibodies tested neutralized the virus. The mechanism underlying these findings was examined in experiments in mice that showed that germinal centers (GCs) formed in the presence of the same antibodies were dominated by low-affinity B cells. Our results indicate that pre-existing high-affinity antibodies bias GC and memory B cell selection by two distinct mechanisms: (1) by lowering the activation threshold for B cells thereby permitting abundant lower-affinity clones to participate in the immune response, and (2) through direct masking of their cognate epitopes. This may in part explain the shifting target profile of memory antibodies elicited by booster vaccinations 9 .

multidisciplinary sciences
Longitudinal analysis of B- and T-cell responses to SARS-CoV-2 recombinant S-protein vaccine S-268019-b in phase 1/2 priming and booster study

Masaya Fujitani,Xiuyuan Lu,Ryo Shinnakasu,Takeshi Inoue,Yujiro Kidani,Naomi M Seki,Satoru Ishida,Shungo Mitsuki,Takeshi Ishihara,Miwa Aoki,Akio Suzuki,Koji Takahashi,Masahiro Takayama,Takeshi Ota,Satoshi Iwata,Risa Yokokawa Shibata,Takuhiro Sonoyama,Mari Ariyasu,Ayumi Kitano,Tommy Terooatea,Jordan Kelly Villa,Kazuo Yamashita,Sho Yamasaki,Tomohiro Kurosaki,Shinya Omoto

DOI: https://doi.org/10.1101/2024.10.01.24314659

2024-10-03

Abstract:The durability of vaccine-induced immune memory to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial for preventing infection, especially severe disease. This follow-up report from a phase 1/2 study of S-268019-b (a recombinant spike protein vaccine) after homologous booster vaccination confirms its long-term safety, tolerability, and immunogenicity. Booster vaccination with S-268019-b resulted in an enhancement of serum neutralizing antibody (NAb) titers and a broad range of viral neutralization. Single-cell immune profiling revealed persistent and mature antigen-specific memory B cells and T follicular helper cells, with increased B-cell receptor diversity. The expansion of B- and T-cell repertoires and presence of cross-reactive NAbs targeting conserved epitopes within the receptor-binding domain following a booster accounted for the broad-spectrum neutralizing activity. These findings highlight the potential of S-268019-b to provide broad and robust protection against a range of SARS-CoV-2 variants, addressing a critical challenge in the ongoing fight against coronavirus disease 2019 (COVID-19).
Dynamic SARS-CoV-2-specific B-cell and T-cell Responses Following Immunization with an Inactivated COVID-19 Vaccine

Yuxin Chen,Shengxia Yin,Xin Tong,Yue Tao,Jun Ni,Jie Pan,Ming Li,Yawen Wan,Minxin Mao,Yali Xiong,Xiaomin Yan,Yue Yang,Rui Huang,Chao Wu,Han Shen

DOI: https://doi.org/10.1016/j.cmi.2021.10.006

IF: 13.31

2021-01-01

Clinical Microbiology and Infection

Abstract:Objective: The dynamic adaptive immune responses elicited by the inactivated virus vaccine CoronaVac remain elusive. Methods: In a prospective cohort of 100 healthcare professionals naive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who received two doses of CoronaVac, we analysed SARS-CoV-2-specific humoral and cellular responses at four different timepoints, including before vaccination (T1), 2 weeks after the first dose (T2), 2 weeks after the booster dose (T3), and 8-10 weeks after the booster dose (T4). SARS-CoV-2-specific antibodies, serum neutralizing activities, peripheral B cells, CD4(+) and CD8(+) T cells and their memory subsets were simultaneously measured in this cohort. Results: SARS-CoV-2 spike-specific IgG responses reached a peak (geometric mean titre (GMT) 54827, 30969-97065) after two doses and rapidly declined (GMT 502, 212-1190) at T4, whereas suboptimal IgA responses were detected (GMT 5, 2-9). Spike-specific circulating B cells (0.60%, 0.46-0.73% of total B cells) and memory B cells (1.18%, 0.92-1.44% of total memory B cells) were effectively induced at T3 and sustained over time (0.33%, 0.23-0.43%; 0.87%, 0.05-1.67%, respectively). SARS-CoV-2-specific circulating CD4(+) T cells (0.57%, 0.47-0.66%) and CD8(+) T cells (1.29%, 1.04-1.54%) were detected at T3. At T4, 0.78% (0.43-1.20%) of memory CD4+ T cells and 0.68% (0.29-1.30%) of memory CD8(+) T cells were identified as SARS-CoV-2-specific, while 0.62% (0.51-0.75%) of CD4(+) T cells and 0.47% (0.38-0.58%) of CD8(+) T cells were SARS-CoV-2-specific terminally differentiated effector memory cells. Furthermore, age and interval between doses affected the magnitude of CoronaVac-induced immune responses. SARS-CoV-2 memory CD4(+) T cells were strongly associated with both receptor binding domain (RBD)-specific memory B cells (r 0.87, p <0.0001) and SARS-CoV-2-specific memory CD8(+) T cells (r 0.48, p <0.0001). Conclusions: CoronaVac induced robust circulating and memory B cell and T cell responses. Our study offers new insight into the underlying immunobiology of inactivated virus vaccines in humans and may have implications for vaccine strategies in the future. (C) 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Memory B cell proliferation drives differences in neutralising responses between ChAdOx1 and BNT162b2 SARS-CoV-2 vaccines

David Hodgson,Yi Liu,Louise Carolan,Siddhartha Mahanty,Kanta Subbarao,Sheena Sullivan,Annette Fox,Adam J Kucharski

DOI: https://doi.org/10.1101/2024.07.11.24310221

2024-07-11

Abstract:Vaccination against COVID-19 has been pivotal in reducing the global burden of the disease. However, Phase III trial results and observational studies underscore differences in efficacy across vaccine technologies and dosing regimens. Notably, mRNA vaccines have exhibited superior effectiveness compared to Adenovirus (AdV) vaccines, especially with extended dosing intervals. Using in-host mechanistic modelling, this study elucidates these variations and unravels the biological mechanisms shaping the immune responses at the cellular level. We used data on the change in memory B cells, plasmablasts, and antibody titres after the second dose of a COVID-19 vaccine for Australian healthcare workers. Alongside this dataset, we constructed a kinetic model of humoral immunity which jointly captured the dynamics of multiple immune markers, and integrated hierarchical effects into this kinetics model, including age, dosing schedule, and vaccine type. Our analysis estimated that mRNA vaccines induced 2.1 times higher memory B cell proliferation than AdV vaccines after adjusting for age, interval between doses and priming dose. Additionally, extending the duration between the second vaccine dose and priming dose beyond 28 days boosted neutralising antibody production per plasmablast concentration by 30%. We also found that antibody responses after the second dose were more persistent when mRNA vaccines were used over AdV vaccines and for longer dosing regimens. Reconstructing in-host kinetics in response to vaccination could help optimise vaccine dosing regimens, improve vaccine efficacy in different population groups, and inform the design of future vaccines for enhanced protection against emerging pathogens.
Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination

Katharina Röltgen,Sandra C A Nielsen,Oscar Silva,Sheren F Younes,Maxim Zaslavsky,Cristina Costales,Fan Yang,Oliver F Wirz,Daniel Solis,Ramona A Hoh,Aihui Wang,Prabhu S Arunachalam,Deana Colburg,Shuchun Zhao,Emily Haraguchi,Alexandra S Lee,Mihir M Shah,Monali Manohar,Iris Chang,Fei Gao,Vamsee Mallajosyula,Chunfeng Li,James Liu,Massa J Shoura,Sayantani B Sindher,Ella Parsons,Naranjargal J Dashdorj,Naranbaatar D Dashdorj,Robert Monroe,Geidy E Serrano,Thomas G Beach,R Sharon Chinthrajah,Gregory W Charville,James L Wilbur,Jacob N Wohlstadter,Mark M Davis,Bali Pulendran,Megan L Troxell,George B Sigal,Yasodha Natkunam,Benjamin A Pinsky,Kari C Nadeau,Scott D Boyd,Sandra C.A. Nielsen,Sheren F. Younes,Oliver F. Wirz,Ramona A. Hoh,Prabhu S. Arunachalam,Alexandra S. Lee,Mihir M. Shah,Massa J. Shoura,Sayantani B. Sindher,Naranjargal J. Dashdorj,Naranbaatar D. Dashdorj,Geidy E. Serrano,Thomas G. Beach,R. Sharon Chinthrajah,Gregory W. Charville,James L. Wilbur,Jacob N. Wohlstadter,Mark M. Davis,Megan L. Troxell,George B. Sigal,Benjamin A. Pinsky,Kari C. Nadeau,Scott D. Boyd

DOI: https://doi.org/10.1016/j.cell.2022.01.018

IF: 64.5

2022-03-01

Cell

Abstract:During the SARS-CoV-2 pandemic, novel and traditional vaccine strategies have been deployed globally. We investigated whether antibodies stimulated by mRNA vaccination (BNT162b2), including third-dose boosting, differ from those generated by infection or adenoviral (ChAdOx1-S and Gam-COVID-Vac) or inactivated viral (BBIBP-CorV) vaccines. We analyzed human lymph nodes after infection or mRNA vaccination for correlates of serological differences. Antibody breadth against viral variants is lower after infection compared with all vaccines evaluated but improves over several months. Viral variant infection elicits variant-specific antibodies, but prior mRNA vaccination imprints serological responses toward Wuhan-Hu-1 rather than variant antigens. In contrast to disrupted germinal centers (GCs) in lymph nodes during infection, mRNA vaccination stimulates robust GCs containing vaccine mRNA and spike antigen up to 8 weeks postvaccination in some cases. SARS-CoV-2 antibody specificity, breadth, and maturation are affected by imprinting from exposure history and distinct histological and antigenic contexts in infection compared with vaccination.

cell biology,biochemistry & molecular biology
SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation

Katlyn Lederer,Diana Castaño,Daniela Gómez Atria,Thomas H Oguin,Sidney Wang,Tomaz B Manzoni,Hiromi Muramatsu,Michael J Hogan,Fatima Amanat,Patrick Cherubin,Kendall A Lundgreen,Ying K Tam,Steven H Y Fan,Laurence C Eisenlohr,Ivan Maillard,Drew Weissman,Paul Bates,Florian Krammer,Gregory D Sempowski,Norbert Pardi,Michela Locci,Thomas H. Oguin,Tomaz B. Manzoni,Michael J. Hogan,Kendall A. Lundgreen,Ying K. Tam,Steven H.Y. Fan,Laurence C. Eisenlohr,Gregory D. Sempowski

DOI: https://doi.org/10.1016/j.immuni.2020.11.009

IF: 32.4

2020-12-01

Immunity

Abstract:The deployment of effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to eradicate the coronavirus disease 2019 (COVID-19) pandemic. Many licensed vaccines confer protection by inducing long-lived plasma cells (LLPCs) and memory B cells (MBCs), cell types canonically generated during germinal center (GC) reactions. Here, we directly compared two vaccine platforms—mRNA vaccines and a recombinant protein formulated with an MF59-like adjuvant—looking for their abilities to quantitatively and qualitatively shape SARS-CoV-2-specific primary GC responses over time. We demonstrated that a single immunization with SARS-CoV-2 mRNA, but not with the recombinant protein vaccine, elicited potent SARS-CoV-2-specific GC B and T follicular helper (Tfh) cell responses as well as LLPCs and MBCs. Importantly, GC responses strongly correlated with neutralizing antibody production. mRNA vaccines more efficiently induced key regulators of the Tfh cell program and influenced the functional properties of Tfh cells. Overall, this study identifies SARS-CoV-2 mRNA vaccines as strong candidates for promoting robust GC-derived immune responses.

immunology
Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2

Tomer Hertz,Shlomia Levy,Daniel Ostrovsky,Hanna Oppenheimer,Shosh Zismanov,Alona Kuzmina,Lilach M. Friedman,Sanja Trifkovic,David Brice,Lin Chun-Yang,Liel Cohen-Lavi,Yonat Shemer-Avni,Merav Cohen-Lahav,Doron Amichay,Ayelet Keren-Naus,Olga Voloshin,Gabriel Weber,Ronza Najjar-Debbiny,Bibiana Chazan,Maureen A. McGargill,Richard Webby,Michal Chowers,Lena Novack,Victor Novack,Ran Taube,Lior Nesher,Orly Weinstein

DOI: https://doi.org/10.1038/s41467-023-39816-4

IF: 16.6

2023-07-30

Nature Communications

Abstract:Vaccination, especially with multiple doses, provides substantial population-level protection against COVID-19, but emerging variants of concern (VOC) and waning immunity represent significant risks at the individual level. Here we identify correlates of protection (COP) in a multicenter prospective study following 607 healthy individuals who received three doses of the Pfizer-BNT162b2 vaccine approximately six months prior to enrollment. We compared 242 individuals who received a fourth dose to 365 who did not. Within 90 days of enrollment, 239 individuals contracted COVID-19, 45% of the 3-dose group and 30% of the four-dose group. The fourth dose elicited a significant rise in antibody binding and neutralizing titers against multiple VOCs reducing the risk of symptomatic infection by 37% [95%CI, 15%-54%]. However, a group of individuals, characterized by low baseline titers of binding antibodies, remained susceptible to infection despite significantly increased neutralizing antibody titers upon boosting. A combination of reduced IgG levels to RBD mutants and reduced VOC-recognizing IgA antibodies represented the strongest COP in both the 3-dose group (HR = 6.34, p = 0.008) and four-dose group (HR = 8.14, p = 0.018). We validated our findings in an independent second cohort. In summary combination IgA and IgG baseline binding antibody levels may identify individuals most at risk from future infections.

multidisciplinary sciences

[Immunological studies on insulin-dependent diabetes mellitus (IDDM). I. Natural killer (NK) cell activity].

Early human B cell signatures of the primary antibody response to mRNA vaccination

Dyscrasias with "undetermined significance".

Affinity-independent memory B cell origin of the early antibody-secreting cell response in naive individuals upon SARS-CoV-2 vaccination

Long-Lasting Enhanced Cytokine Responses Following SARS-CoV-2 BNT162b2 mRNA Vaccination

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination – kinetics of plasma antibodies, plasmablasts and memory B cells

Speak up ... if you dare: raising concerns about colleagues you suspect of bad practice is not easy in a working culture that views whistle-blowing as 'telling tales'.

SARS-CoV-2 Omicron BA.1 breakthrough infection drives late remodeling of the memory B cell repertoire in vaccinated individuals

Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections

Cellular basis of enhanced humoral immunity to SARS-CoV-2 upon homologous or heterologous booster vaccination analyzed by single-cell immune profiling

Antibody feedback regulation of memory B cell development in SARS-CoV-2 mRNA vaccination

mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern

Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing

Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination

Longitudinal analysis of B- and T-cell responses to SARS-CoV-2 recombinant S-protein vaccine S-268019-b in phase 1/2 priming and booster study

Dynamic SARS-CoV-2-specific B-cell and T-cell Responses Following Immunization with an Inactivated COVID-19 Vaccine

Memory B cell proliferation drives differences in neutralising responses between ChAdOx1 and BNT162b2 SARS-CoV-2 vaccines

Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination

SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation

Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2